BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

973 related articles for article (PubMed ID: 32889241)

  • 21. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study.
    Hirashima T; Arai T; Kitajima H; Tamura Y; Yamada T; Hashimoto S; Morishita H; Minamoto S; Kawashima K; Kashiwa Y; Kameda M; Takeshita T; Suzuki H; Matsuoka H; Yamaguchi S; Tanaka T; Nagai T
    J Infect Chemother; 2021 Jan; 27(1):76-82. PubMed ID: 33051144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Appropriate use of tocilizumab in COVID-19 infection.
    Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
    Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
    Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
    Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
    Addeo A; Obeid M; Friedlaender A
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32434788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [First case of COVID-19 treated with tocilizumab in Iceland].
    Bjornsson AH; Olafsdottir T; Thormar KM; Kristjansson M; Thorisdottir AS; Ludviksson BR; Guðmundsson S; Gottfredsson M
    Laeknabladid; 2020 Mai; 106(5):247-250. PubMed ID: 32367812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
    Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
    Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.
    Fragoso-Saavedra S; Iruegas-Nunez DA; Quintero-Villegas A; García-González HB; Nuñez I; Carbajal-Morelos SL; Audelo-Cruz BM; Arias-Martínez S; Caro-Vega Y; Calva JJ; Luqueño-Martínez V; González-Duarte A; Crabtree-Ramírez B; Crispín JC; Sierra-Madero J; Belaunzarán-Zamudio PF; Valdés-Ferrer SI
    BMC Infect Dis; 2020 Oct; 20(1):765. PubMed ID: 33066761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
    Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
    Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
    Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
    PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Audio Interview: Tocilizumab and Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.
    Masiá M; Fernández-González M; Padilla S; Ortega P; García JA; Agulló V; García-Abellán J; Telenti G; Guillén L; Gutiérrez F
    EBioMedicine; 2020 Oct; 60():102999. PubMed ID: 32950003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
    Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
    BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribavirin therapy for severe COVID-19: a retrospective cohort study.
    Tong S; Su Y; Yu Y; Wu C; Chen J; Wang S; Jiang J
    Int J Antimicrob Agents; 2020 Sep; 56(3):106114. PubMed ID: 32712334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective treatment of severe COVID-19 patients with tocilizumab.
    Xu X; Han M; Li T; Sun W; Wang D; Fu B; Zhou Y; Zheng X; Yang Y; Li X; Zhang X; Pan A; Wei H
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10970-10975. PubMed ID: 32350134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
    Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
    Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.